TNYA vs. PGEN, ADAP, QURE, ABSI, BCAB, DNA, FDMT, BCRX, AUTL, and IMTX
Should you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Precigen (PGEN), Adaptimmune Therapeutics (ADAP), uniQure (QURE), Absci (ABSI), BioAtla (BCAB), Ginkgo Bioworks (DNA), 4D Molecular Therapeutics (FDMT), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), and Immatics (IMTX). These companies are all part of the "medical" sector.
Precigen (NASDAQ:PGEN) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
In the previous week, Tenaya Therapeutics had 8 more articles in the media than Precigen. MarketBeat recorded 9 mentions for Tenaya Therapeutics and 1 mentions for Precigen. Tenaya Therapeutics' average media sentiment score of 1.87 beat Precigen's score of 0.78 indicating that Precigen is being referred to more favorably in the media.
Precigen presently has a consensus price target of $9.00, indicating a potential upside of 542.86%. Tenaya Therapeutics has a consensus price target of $15.00, indicating a potential upside of 256.29%. Given Tenaya Therapeutics' higher possible upside, research analysts plainly believe Precigen is more favorable than Tenaya Therapeutics.
Precigen received 403 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. However, 75.76% of users gave Tenaya Therapeutics an outperform vote while only 67.08% of users gave Precigen an outperform vote.
Precigen has higher revenue and earnings than Tenaya Therapeutics. Precigen is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tenaya Therapeutics has a net margin of 0.00% compared to Tenaya Therapeutics' net margin of -1,781.72%. Tenaya Therapeutics' return on equity of -65.36% beat Precigen's return on equity.
Precigen has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.61, suggesting that its share price is 161% more volatile than the S&P 500.
33.5% of Precigen shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 41.7% of Precigen shares are held by company insiders. Comparatively, 32.8% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Precigen beats Tenaya Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Tenaya Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenaya Therapeutics Competitors List
Related Companies and Tools
